PMID- 24265750
OWN - NLM
STAT- MEDLINE
DCOM- 20140903
LR  - 20220410
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 11
DP  - 2013
TI  - Human papillomavirus type-specific prevalence in the cervical cancer screening 
      population of Czech women.
PG  - e79156
LID - 10.1371/journal.pone.0079156 [doi]
LID - e79156
AB  - BACKGROUND: Infection with high-risk human papillomavirus (HPV)types has been 
      recognized as a causal factor for the development of cervical cancer and a number 
      of other malignancies. Today, vaccines against HPV, highly effective in the 
      prevention of persistent infection and precancerous lesions, are available for 
      the routine clinical practice. OBJECTIVES: The data on the prevalence and 
      type-specific HPV distribution in the population of each country are crucial for 
      the surveillance of HPV type-specific prevalence at the onset of vaccination 
      against HPV. METHODS: Women attending a preventive gynecological examination who 
      had no history of abnormal cytological finding and/or surgery for cervical 
      lesions were enrolled. All samples were tested for the presence of HPV by 
      High-Risk Hybrid Capture 2 (HR HC2) and by a modified PCR-reverse line blot assay 
      with broad spectrum primers (BS-RLB). RESULTS: Cervical smears of 1393 women were 
      analyzed. In 6.5% of women, atypical cytological findings were detected. 
      Altogether, 28.3% (394/1393) of women were positive for any HPV type by BS-RLB, 
      18.2% (254/1393) by HR HC2, and 22.3% (310/1393) by BS-RLB for HR HPV types. In 
      women with atypical findings the prevalence for HR and any HPV types were 
      significantly higher than in women with normal cytological findings. Overall, 36 
      different HPV types were detected, with HPV 16 being the most prevalent (4.8%). 
      HPV positivity decreased with age; the highest prevalence was 31.5% in the age 
      group 21-25 years. CONCLUSIONS: Our study subjects represent the real screening 
      population. HPV prevalence in this population in the Czech Republic is higher 
      than in other countries of Eastern Europe. Also the spectrum of the most 
      prevalent HPV types differs from those reported by others but HPV 16 is, 
      concordantly, the most prevalent type. Country-specific HPV type-specific 
      prevalences provide baseline information which will enable to measure the impact 
      of HPV vaccination in the future.
FAU - Tachezy, Ruth
AU  - Tachezy R
AD  - Department of Experimental Virology, Institute of Hematology and Blood 
      Transfusion, Prague, Czech Republic.
FAU - Smahelova, Jana
AU  - Smahelova J
FAU - Kaspirkova, Jana
AU  - Kaspirkova J
FAU - Salakova, Martina
AU  - Salakova M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131112
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Alphapapillomavirus/genetics/*physiology
MH  - Czech Republic/epidemiology
MH  - DNA, Viral/analysis
MH  - Epidemiological Monitoring
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Species Specificity
MH  - Uterine Cervical Neoplasms/*diagnosis/epidemiology/prevention & control/*virology
MH  - Vaccination
MH  - Young Adult
PMC - PMC3827175
COIS- Competing Interests: Biopticka laboratory is a private company providing routine 
      pathological, cytological and molecular genetic diagnostics of human clinical 
      samples. The co-author, Jana Kaspirkova, is a molecular geneticist who is 
      responsible for appropriate sample collection and who contributed to the data 
      analysis. There is no potential conflict of interest concerning the study results 
      and she confirms that this does not alter the adherence to all the PLOS ONE 
      policies on sharing data and materials.
EDAT- 2013/11/23 06:00
MHDA- 2014/09/04 06:00
PMCR- 2013/11/12
CRDT- 2013/11/23 06:00
PHST- 2013/06/21 00:00 [received]
PHST- 2013/09/26 00:00 [accepted]
PHST- 2013/11/23 06:00 [entrez]
PHST- 2013/11/23 06:00 [pubmed]
PHST- 2014/09/04 06:00 [medline]
PHST- 2013/11/12 00:00 [pmc-release]
AID - PONE-D-13-25671 [pii]
AID - 10.1371/journal.pone.0079156 [doi]
PST - epublish
SO  - PLoS One. 2013 Nov 12;8(11):e79156. doi: 10.1371/journal.pone.0079156. 
      eCollection 2013.